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ABSTRACT Insulin-dependent diabetes meflitus is a mul-
tigenic autimmune disease, for which one of the best animal
models is the nonobese diabetic (NOD) mouse strain. In both
humans andNOD mice, major histocompatibility complex genes
are implicated as risk factors in the disease process. Other
susceptibility genes are also involved, and a number have been
mapped in the mouse to specific chromosomal locations. To
identify further susceptibility genes, diabetic backcross mice,
produced after crossing NOD/Lt to the nondiabetic strains SJL
and C57BL/6 (B6), were examined for markers not previously
associated with disease susceptibility. Linkage was found to loci
on chromosomes 4 and 14. Ofthe c ate loci on chromosome
4, the gene encoding the Na+/H+ exchanger-1, Nhe-i, was the
most likely, since the NOD allele was different from that of both
nondiabetic strains. NOD lymphocytes were found to have a
higher level of Na+/H+ exchange activity than lymphocytes
from either B6 or SJL mice. Since the chromosome 4 suscepti-
bility gene is recessive, the B6 allele should prevent diabetes.
This prediction was tested in fourth-generation backcross mice,
selected for retention ofthe B6 allele atNhe-l. Mice homozygous
forNhe-i developed diabetes after cyclophosphamide treatment,
but heterozygotes were largely protected from disease. These
results implicate the Na+/H+ exchanger (antiporter) in the
development of type 1 diabetes and may provide a screening test
for at-risk individuals as well as offering prospects for disease
prevention.
Insulin-dependent diabetes mellitus is characterized by lym-
phocytic infiltration of the pancreatic islets, in which T
lymphocytes mediate the destruction of insulin-producing j3
cells. Perhaps the best animal model of insulin-dependent (or
type 1) diabetes is the nonobese diabetic (NOD) mouse strain
(1), which has been the subject of many immunological and
genetic studies aimed at defining the properties that contrib-
ute to disease susceptibility. In both humans and NOD mice,
genes mapping to the major histocompatibility complex are
important in the disease process (2). In NOD mice, this gene
conferring insulin-dependent diabetes susceptibility is
termed Idd-1.
Despite the importance of the major histocompatibility
complex to the disease process, other genes also contribute.
Their nature is not well defined in the human disease, but
genetic analyses of NOD mice have revealed that several
genes are involved. Some of these have been mapped to
specific chromosomal locations, although their products
have not been identified (3-6). These diabetes susceptibility
genes (DSG) are numbered from Idd-2, which is linked to the
Thy-i gene on chromosome 9 (7). Todd et al. (3) defined the
Idd-3 and Idd4 loci on chromosomes 3 and 11, which
influence occurrence ofdiabetes and time of onset of disease.
A further gene on chromosome 1 was implicated in periin-
sulitis and the lymphocytic infiltration observed in various
other organs ofNOD mice, such as the salivary glands (4, 8).
Another gene was mapped to chromosome 15 by using an
interspecies backcross (6). In a report to appear elsewhere,
we show that diabetes susceptibility alleles are shared by
strains of mice that do not develop diabetes (A.B., unpub-
lished data). This study also suggested that there were
additional DSG that had not been defined previously. We
now report data that map previously undisclosed DSG to
mouse chromosomes 4 and 14.
MATERIALS AND METHODS
Mice. NOD/Lt, C57BL/6 (B6), and SJL mice were obtained
from the Walter and Eliza Hall Institute specific pathogen-free
facilities and maintained in a conventional mouse colony.
Diabetic H-2 7-homozygous female mice from the NOD/Lt x
(B6 x NOD/Lt) and NOD/Lt x (SJL x NOD/Lt) back-
crosses were obtained as will be described elsewhere (A.B.,
unpublished data). Briefly, first generation backcross females,
selected for the absence of H-2 antigens of the nondiabetic
strain, were monitored for the development of diabetes by
testing blood glucose levels at 2-week intervals. BC1 males
were crossed to NOD/Lt and progeny were screened for
heterozygosity at Nhe-1, the gene encoding the Na+/H+
exchanger 1 (NHE-1). Further backcrossing and selection
produced an incipient NOD/Nhe-1 congenic line.
Genetic Analyses. Diabetic mice from each backcross were
typed as described at loci in which NOD alleles were shown
to differ from both B6 and SJL alleles (9). Restriction
fragment length polymorphisms were typed by hybridization
to nylon membranes (Amersham) according to the manufac-
turer's recommendations. Microsatellite markers were ana-
lyzed (10) by using primers obtained from Research Genetics
(Huntsville, AL).
To define the chromosomal localization of putative DSG,
the backcross panels were typed for inheritance of alleles
from the nondiabetic strain at further loci on chromosomes 4
and 14. Markers were chosen according to their position on
distal chromosome 4 (11) or on the corresponding region of
the human genome-i.e., chromosome 1p; these loci have
since been placed on the mouse map by typing recombinant
inbred strains (P.M., unpublished data). The order of micro-
satellite markers and their position relative to other chromo-
some 4 loci were taken from the data ofDietrich et al. (10) and
of P.M. (unpublished data). Chromosome 14 marker posi-
tions were from refs. 10 and 11 and from the Whitehead/MIT
Center for Genome Research "Genetic Map of the Mouse"
Database Release 3, 1993. Probes detecting previously un-
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described polymorphisms between NOD and the nondiabetic
strains were Gcsfr and Gcsfr-rs (N. Gough, personal com-
munication), Lck (12), Lap-18 (13), ang (14), Tcra-Va8 (15),
and Rb-i (16). Nhe-i alleles were typed by using a human
cDNA probe (17) as described (18).
Measurement ofNa+/H+ Exchange Activit. Pooled spleen
and lymph node cell suspensions from B6, SJL, and nondi-
abetic NOD mice were erythrocyte-depleted and loaded with
the pH-sensitive dye BCECF [2',7'-bis(2-carboxyethyl)-5(6)-
carboxyfluorescein] as described (19). Fluorescence mea-
surements were made with a dual wavelength fluorimeter
CM-2 (Spex Industries, Metuchen, NJ). Cells were acidified
for experiments and for construction of the calibration curve
by the "nigericin-clamp" technique; all measurements were
made in cells from which nigericin was removed by washing
with solutions containing bovine serum albumin. A 100-p1
aliquot of each cell suspension was added rapidly to 2.9 ml of
stirred physiological saline solution (135 mM NaCl/5 mM
KCl/1.8 mM CaCl2/0.8 mM MgSO4/5.5 mM glucose/10 mM
Hepes, pH 7.35 at 37°C) in a thermostated cuvette at 37°C.
Kinetic rates were determined from the initial phase (15-20
s) of alkalinization. All data were derived from at least two
different lymphocyte preparations and were analyzed by
Student's t test and ANOVA.
As antiporter measurements can be complicated by differ-
ences in buffer capacity, this parameter was determined (20)
at a nominal pH value of 6.49 (the midpoint of the experi-
mental range). NOD lymphocytes had a buffer capacity of
64.2 9.3 mmol per liter per pH unit (n = 4) at an
experimentally determined intracellular pH (pHi) of 6.44 +
0.03; B6 lymphocyte buffer capacity was 44.2 ± 9.2 mmol per
liter per pH unit (n = 4; pH1 of 6.52 ± 0.03). These values
were not significantly different (P > 0.1; unpaired Student's
t test) and were similar to others in the literature.
Induction of Diabetes. Cyclophosphamide was used to
induce diabetes (21, 22) at a dose of350 mg/kg ofbody weight
in mice of the fourth or sixth backcross generations of the
incipient NOD/Nhe-lb congenic strain. Diabetes status was
monitored over 2-4 weeks by testing either random blood
glucose or urinary glucose levels.
RESULTS
Identifcation of Previously Unreported DSG. To detect
genes that could confer disease susceptibility, backcross
mice (produced after crossing NOD/Lt to the nondiabetic
strains SJL and B6) were examined for inheritance of mark-
ers on chromosomes not associated with susceptibility. Fe-
male mice were selected for homozygosity of NOD H-2,
which is necessary for development of diabetes (2). Over 200
of these H-297-homozygous backcross mice were monitored
for diabetes. Ten diabetic mice from each panel were as-
sessed for inheritance ofmarkers linked to Idd-2-Idd-7 (A.B.,
unpublished data) and were typed at loci on other chromo-
somes (Table 1).
As expected, most of the loci tested showed no evidence
of linkage to disease. However, significant homozygosity of
NOD alleles was found at loci on chromosomes 4 and 14. To
evaluate this observation, 30 nondiabetic mice from the B6
backcross were chosen at random and typed at these loci.
The results did not deviate from that expected from Mende-
lian inheritance: 14 of 30 were heterozygous at D4Mit71,
while 17 of 30 were heterozygous at D14Mitli. Therefore,
there was no selective disadvantage of heterozygosity of
NOD alleles at these loci. These results suggest linkage of
potential DSG to markers on chromosomes 4 and 14.
Mapping of the DSG on Chromosome 4. A number ofgenes
on distal chromosome 4 could potentially be involved in
aberrant immune responses. To exclude some of these, the
backcross panels were typed at flanking markers on this
chromosome (Table 2). All but one of the B6 backcross
diabetic mice were homozygous at the chromosomal region
from Lck to Lap-18. Crossovers occurred in this panel
between Lck (12) and D4Mit72 and between Lap-18 and
D4Miti3 (10). These results exclude as candidate suscepti-
bility genes the Gcsfr, c-jun, and TNFR2 loci as well as Glut-i
and Mls-2, both of which are proximal to Gcsfr. Instead, the
most likely location of a chromosome 4 DSG is between
D4Mit72 and D4Miti3. This distance is less than 10 centi-
morgans (cM) estimated from typing recombinant inbred
strains (not shown). Similar results were obtained in the SJL
panel: all but one of the mice were homozygous at Nhe-i on
distal chromosome 4, while another two were heterozygous
at the most proximal marker typed, c-jun. Similar analyses
suggested that the most likely location for the DSG on
chromosome 14 is proximal to D14Mit45 (Table 2).
Four genes mapping to the D4Mit72-D4Miti3 interval
were considered as candidates for the chromosome 4 DSG:
Lck (12), involved in T-cell activation; Nhe-i (18), which
Table 1. Genotype of diabetic backcross mice at polymorphic markers on chromosomes not previously known to contain diabetes
susceptibility genes
B6 allele
Prt-cpnt-- in hnokornee mmilep nuirnhor
SJL allele
Vropa,%%.-v ;inwso~oXe srarkmrIVVII% £1 VU44;AIOlIIWUJ51IU3UI No. Pren mU uaCD .UTIIImuse iInum i No.
Locus Chr. 7 19 24 36 48 68 72 94 98 138 het. 16 23 29 32 47 50 65 84 86 92 het. x2
D4Mitll 4 * * 2 * 1 8.46
D5Mitl6 5 * * * * * 5 * * * * * 5 0.05
D8MitlS 8 * * * * 4 * * * * * 5 0.05
DlOMit2O 10 * * * * * 5 * * 2 1.25
D12Mit4 12 * * * * * * 6 * * * * * * * 7 1.25
D13Mit9 13 * * * * * * * * 8 * * * * * 5 1.25
D14Mitll 14 * * 2 * 1 8.46
D16Mitli 16 * * * * 4 * * * * * 5 0.05
D18Miti2 18 * * * * 4 * * * * * 5 0.05
GCSFR-rs 19 * * * * * * 6 * * * * 4 0.05
Ten diabetic mice (each numbered) from each backcross panel were typed for inheritance of B6 or SJL alleles of loci at which NOD mice
had been shown (9) to differ from both of these strains. Presence of nondiabetic strain alleles is indicated by an asterisk. Linkage to previously
described DSG on chromosomes 1, 3, 6, 7, 9,11, 15, and 17 and to the GAD locus on chromosome 2 will be analyzed elsewhere (A.B., unpublished
data). There was no significant difference between the backcross panels for any of these markers by Fischer's exact test, so these results were
pooled. Results of Yates' corrected x2 test are shown. V2 values > 3.84 indicate significance at the P = 0.05 level; and values > 10.83, at the
0.001 level. Although usually corrections are not made for multiple tests (e.g., ref. 6), such an allowance may be made by dividing a by the number
of tests; in this case, for testing linkage to 10 markers, a V2 value > 7.88 indicates significant linkage (P < 0.05). Chr., chromosome; No. het.,
number of heterozygotes.
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Table 2. Mapping of diabetes susceptibility genes on mouse chromosomes 4 and 14
B6 allele SJL allele
Presence in backcross mouse number No. Presence in backcross mouse number No.
Locus Chr. 7 19 24 36 48 68 72 94 98 138 het. 16 23 29 32 47 50 65 84 86 92 het. x2
c-jun 4 = = = = = = = = = = * * * 3
D4Mitll 4 * * 2 * 1 8.46
Gcsfr 4 * * 2 = = = = = = = = = =
D4Mit72 4 * * 2 * 1 8.46
Lck 4 * 1 = = = = = = = = = =
D4MUit71 4 * 1 = = = = = = = = = =
Nhe-1 4 * 1 * 1 11.3
Lap-18 4 * 1 = = = = = = = = = =
D4Mitl3 4 * * 2 = = = = = = = = = =
TNFR2 4 * * 2 = = = = = = = = = =
D14Mitl 14 * * 2 = = = = = = = = = =
D14Mit40 14 * * 2 * 1 8.46
Dl4Mitll 14 * * 2 = = = = = = = = = =
D14Mit44 14 * * 2 * 1 8.46
D14Mit45 14 * * * 3 * * 2 4.05
D14MUitl8 14 * * 2 = = = = = = = = = =
D14Mit4 14 * * 2 = = = = = = = = = =
Ang 14 * * 2 = = = = = = = = = =
Tcra 14 * * 2 = = = = = = = = = =
D14Mit30 14 * * 2 = = = = = = = = = =
Rb-I 14 * * 2 = = = = = = = = = =
Diabetic backcross mice shown in Table 1 were analyzed for inheritance of markers on chromosomes 4 and 14. The presence of nondiabetic
strain alleles is indicated by an asterisk; an equal sign (=) indicates no polymorphism found between the nondiabetic strain and NOD. Results
of Yates' corrected x2 test are shown where both B6 and SJL differ from NOD. Chr., chromosome; No. het., number heterozygous alleles.
regulates intracellular pH, cell volume, and other aspects of
maintenance of cellular viability, particularly after activation
(17, 23); Lap-18, the mouse homologue of a human gene
encoding a phosphoprotein in leukemia cells (13); and ClqC
(ref. 24; P.M., unpublished data), which directs the synthesis
of the B chain of the major complement component. A
candidate gene should vary between NOD and both of the
nondiabetic strains, since linkage to chromosome 4 was
observed in both backcross panels. Polymorphisms were
indeed found (Fig. 1), butNOD and SJL strains shared alleles
at three of these loci, consistent with other observations of
these surprisingly closely related strains (9). Only the Nhe-1
locus was variable between NOD and the other strains;
indeed, this locus has at least three alleles. Naturally, the
inability to find polymorphisms between NOD and SJL at the
other loci does not prove that they are invariant, but even
sequence differences, were they to be found, may not be
A B c D
B N S B N S BN S B N S
FIG. 1. Analysis of candidate genes. Polymorphisms were de-
tected in DNA isolated from B6 (lanes B), NOD/Lt (lanes N), and
SJL (lanes S) mice by using probes for the following genes on distal
mouse chromosome 4: Lck (12) (A); Nhe-1 (18) (B); Lap-18 (13) (C);
and ClqC (24) (D). The map positions of Lap-18 and Clq are to be
described elsewhere (P.M., unpublished data).
biologically relevant. Therefore, demonstration of functional
differences between alleles of these strains is crucial.
Na+/H+ Exchange Actity Varies Between NOD and the
Nondiabetic Strains. The product of the Nhe-1 gene is re-
sponsible for the maintenance ofpHi by transferring Na+ and
H+ ions across the cell membrane (23). To test whether there
was a physiological difference in the activity of the NHE-1
molecule, NOD and B6 lymphocytes were examined for their
ability to regulate pHi (Fig. 2). NOD lymphocytes had a
higher resting intracellular pH than did B6 cells (Fig. 2A).
Furthermore, antiporter activity (indicated by recovery from
induced intracellular acidosis) was higher in cells from NOD
mice than in those from either B6 or SJL mice (Fig. 2 B and
C). Therefore, Nhe-1, differing in both genetics and function
between NOD and the nondiabetic strains, is the best can-
didate for a DSG on mouse chromosome 4.
Role of the Nhe-l-Linked DSG in Cyclophosphamide-
Induced Diabetes. To confirm that the DSG on chromosome
4 was involved in diabetes susceptibility, we started produc-
tion of Nhe-1 congenic strains by repeated backcrossing to
the NOD/Lt strain, selecting at each generation for the
presence ofthe B6 allele (i.e., Nhe-lb; ref. 18) or the D4Mit71
microsatellite, which is within 1 centimorgan (P.M., unpub-
lished data). After four backcross generations, mice were
homozygous for NOD alleles at H-2, at markers linked to
Idd-2-Idd-5, and at the chromosome 14 DSG mapped in
Table 2. The ability of the B6 allele of Nhe-1 to offer
protection from diabetes was tested by cyclophosphamide
treatment, which accelerates the onset of diabetes in NOD
mice (21, 22). Mice were monitored up to 4 weeks after
treatment. Table 3 compares the diabetes incidence in NOD/
Nhe-1a homozygous and NOD/Nhe-la/b mice of the fourth
backcross generation. Most of the Nhe-1 homozygous mice
developed diabetes (Table 3) and did so with a frequency
similar to that observed in cyclophosphamide-treated
NOD/Lt mice in our hands (not shown). In contrast, their
heterozygous littermate mice were largely protected from
cyclophosphamide-induced disease (Table 3). Therefore, ho-
mozygosity ofNOD alleles at Nhe-1 or a very closely linked
Proc. Natl. Acad Sci. USA 91 (1994)
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D4Mit69 (not shown) which is 1 centimorgan distal to Nhe-1
(P.M., unpublished data).
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FIG. 2. Comparison ofNa+/H+ exchange activity. (A) Measure-
ment ofresting pHi in B6 [n (number ofmeasurements) = 5] andNOD
(n = 6) lymphocytes. (B) Rates ofpHi recovery from induced acidosis
at differing pH. Four determinations were made over the initial 20 s
after acidification for each strain at each point (i.e., pH 6.49, 6.34,
and 6.22). (C) Maximal rate of pHi recovery in B6 (n = 8), NOD (n
= 6), and SJL (n = 5) lymphocytes. Asterisks in A and B indicate
significant values (P < 0.001 in A; P < 0.05 in B).
locus are required for diabetes development (in this case,
after cyclophosphamide treatment), consistent with a reces-
sive DSG. Similar results were obtained with heterozygous
mice from the sixth backcross generation, at which stage the
mice were homozygous for NOD alleles at loci distal to
Table 3. Diabetes resistance in NOD/Nhe-lb congenic mice
Presence of Nhe-lb Diabetic mice
allele No. diabetic/total % P
9/13 69
+ 3/12 25 <0.05
Fourth generation backcross mice were typed for inheritance of
the B6 allele of Nhe-l or the closely linked microsatellite marker
D4Mit7l. Cyclophosphamide was used to induce diabetes (21, 22).
Diabetes status was monitored over 2-4 weeks by testing both
random blood glucose and urinary glucose levels. Results of two
separate experiments were combined and analyzed by Fischer's
exact test.
DISCUSSION
Evidence is presented here ofpreviously unreported diabetes
susceptibility genes mapping to distal mouse chromosome 4
and to proximal chromosome 14. It was possible to exclude
a number of loci on chromosome 4 that otherwise may have
been considered for playing a role in autoimmunity-e.g.,
genes encoding glucose transporter 1 and receptors for gran-
ulocyte colony-stimulating factor (G-CSF) and tumor necro-
sis factor (TNF); oncogene c-jun; and the Mls-2 locus. The
best candidate for the DSG on distal chromosome 4 was
Nhe-1. Of the known genes mapping to the relevant region,
it alone displays molecular variation between NOD mice and
each of the other strains used in this study (Fig. 1). Further-
more, this genetic variation has biological relevance: both
basal pHi and Na+/H+ exchange activity, mediated by the
product of this locus, are higher in NOD mice than in either
B6 or SJL mice (Fig. 2).
Although the mapping panel we used was relatively small,
the results nevertheless implicated unreported disease genes;
we welcome investigations of these genes in larger studies.
Recently, other DSG (Idd-8 and -9) were mapped to chro-
mosomes 4 and 14 (25). However, the chromosome 4 DSG
(Idd-9) appears more distal than D4Mitl3 and consequently
cannot be Nhe-1. Furthermore, the incipient congenic strain
does not retain B6 alleles distal to D4Mitl3 (not shown).
Therefore, we provisionally designate the DSG linked to
Nhe-1 as Idd-11. Although the chromosome 14 locus mapped
here is near Idd-8 (25), it confers susceptibility, whereas the
NOD allele of-Idd-8 was described as having a protective
effect (3, 25). Further characterization of this gene, provi-
sionally designated Idd-12, is needed.
The question may be asked as to why Nhe-1 was not
identified previously as a DSG. Susceptibility was not found
to be linked to chromosome 4 in a larger study (3). However,
it is significant that this investigation used B10-H-2g7 as a
nondiabetic partner. Although the B6 and C57BL/10 (B10)
strains are often considered virtually identical, we found they
differed at a number of loci on chromosome 4 (26). Moreover,
B10 strains had the same Nhe-1 allele as in NOD mice (26).
This observation both makes it unlikely that homozygosity of
NOD alleles in this region ofchromosome 4 would have been
selected (3) and strengthens the case for the involvement of
Nhe-1 in diabetes susceptibility.
The protection from cyclophosphamide-induced diabetes
offered by heterozygosity of Nhe-1 may be contrasted with
that of the only previously proven DSG, which encodes the
unique NOD class II molecule (2). NOD mice transgenic for
other class II alleles, such as I-Ak, normally do not develop
spontaneous diabetes. However, NOD/I-Ak transgenic mice
are not protected from developing cyclophosphamide-
induced diabetes (27). The ability of the B6 ("diabetes
resistance") allele of Nhe-1, present in heterozygous con-
genic mice, to prevent even the powerful diabetes-inducing
activity of cyclophosphamide indicates that this gene is
important in the diabetogenic process.
The role played by Nhe-J in the development of diabetes
in NOD mice is unclear because of its ubiquitous cellular
expression and involvement in many cellular processes (23).
Given the importance of pHi, it was surprising to find such a
clear difference in basal pH between cells from NOD and
other strains. This difference could be attributed to increased
levels of Na+/H+ exchange activity, mediated by NHE-1.
Recessive gene products usually are defective in some ac-
tivity; the NOD allele of Nhe-1 is unusual in that it confers a
higher level of activity.
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Significantly, high NHE-1 activity may also be involved in
human diabetes. Antiporter levels are often elevated in cells
obtained from diabetic patients (e.g., refs. 28-30). These
studies may be complicated by the observation that diabetes
per se may lead to raised antiporter levels-e.g., drug-
induced diabetic rats have elevated antiporter activity (31).
Such complications may be avoided by analysis of cultured
cells. Fibroblasts from type I diabetes patients with nephrop-
athy had high antiporter levels; this was taken as evidence
that such patients were predisposed to hypertension and
hence nephropathy (32). In contrast, the present results
implicate high antiporter activity as playing a causal role in
diabetes development, changing the focus ofthe involvement
ofNhe-1 to its predisposing first to diabetes and subsequently
to nephropathy.
Earlier studies that showed elevated antiporter levels in
diabetic patients without proteinuria (28, 29) should be con-
firmed by analyses of cultured cells. However, it is clear that
the disease ofNOD mice may share similar etiology with at
least a subset of type I diabetes patients. Just as NOD mice
and Caucasoid diabetic patients have similar unique MHC
genes, high levels of antiporter activity may also be shared by
certain susceptible individuals in both species. If so, this
provides the basis for a genetic screening test to identify
those who are at risk of developing this autoimmune disease
and its most severe consequences.
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